Vagus nerve stimulation suppresses seizures not by acting on the seizure focus directly, but by modulating the brainstem nuclei that regulate cortical excitability. When electrical pulses reach the vagus nerve’s afferent fibres, they travel to the nucleus tractus solitarius (NTS) in the medulla — the nerve’s primary brainstem relay station. From the NTS, signals propagate to the locus coeruleus (the brain’s main source of norepinephrine) and the dorsal raphe nucleus (its primary serotonin source). The resulting release of norepinephrine and serotonin into the hippocampus, cortex, and thalamocortical circuits raises the threshold for seizure initiation and disrupts the hypersynchronous neuronal firing that defines an epileptic seizure. This mechanism — an afferent brainstem pathway driving widespread cortical desynchronisation through monoamine modulation — explains both why VNS works and why its effects take time to fully develop.
The Neuroanatomical Pathway: From Vagus to Cortex
Understanding why VNS works requires tracing the signal from the stimulating electrode to the cortical networks involved in seizure generation. The vagus nerve carries approximately 80 percent afferent (body-to-brain) fibres, and it is these sensory fibres — not the motor fibres that control heart rate or digestion — that mediate the anti-seizure effect. Electrical stimulation of these afferents at the cervical vagus activates the NTS, which has direct and indirect projections to several critical structures.
The locus coeruleus (LC) is the most important downstream target. A landmark 1998 rat study demonstrated that lesioning the LC completely blocked VNS efficacy, establishing it as a necessary node in the anti-seizure pathway. The LC projects noradrenergic fibres throughout the cortex and hippocampus. Microdialysis studies in rats confirmed that VNS increases extracellular norepinephrine concentrations in the hippocampus and cortex — regions directly involved in seizure generation and propagation. Norepinephrine raises the firing threshold of neurons in these regions, making them less likely to participate in the synchronised bursting that constitutes a seizure.
The dorsal raphe nucleus (DRN) provides the second arm of the mechanism. VNS activates DRN serotonin neurons indirectly, after LC activation. In a DBA/1 mouse model of sudden unexpected death in epilepsy (SUDEP), optogenetic activation of DRN serotonin neurons was anticonvulsant and suppressed the seizure-induced respiratory arrest that causes SUDEP. Both monoamines — norepinephrine and serotonin — are required for the cortical plasticity effects of VNS, as demonstrated in rat studies where depleting either transmitter alone abolished VNS-induced cortical reorganisation.
At the circuit level, these monoamine changes produce measurable EEG desynchronisation. In patients who respond to VNS, electroencephalography shows reduced hypersynchrony in both the acute stimulation period and the long-term resting state. The thalamocortical circuits that propagate generalised seizures are particularly sensitive to noradrenergic modulation, which explains why VNS can be effective across seizure types — not only focal seizures but also generalised tonic-clonic and absence seizures.
Progressive Improvement: A Unique Clinical Signature
VNS differs from almost every other epilepsy treatment in one striking way: its effectiveness increases over time rather than diminishing. Most anti-seizure medications reach peak efficacy within weeks, and some lose effectiveness through pharmacological tolerance. VNS shows the opposite pattern.
In the pivotal clinical trials, approximately 25–30 percent of patients achieved a 50 percent or greater seizure reduction within the first three months. By one to two years, that responder rate climbed to approximately 50 percent. A subset of patients — roughly 5–8 percent — eventually achieved complete seizure freedom. A 2023 systematic review in Frontiers in Neurology confirmed this progressive improvement pattern across multiple studies, with responder rates continuing to increase through year three and beyond.
The biological explanation for this delayed, cumulative benefit is not fully established, but three mechanisms are proposed. First, chronic VNS may gradually upregulate GABA-A receptor density in the cortex, strengthening inhibitory neurotransmission over months. Second, VNS promotes hippocampal neurogenesis — the growth of new neurons in the hippocampus — which may slowly rebuild inhibitory circuits damaged by chronic seizure activity. Third, the progressive strengthening of noradrenergic tone in cortical and limbic regions may produce long-term changes in neuronal excitability that accumulate with sustained stimulation. Whatever the precise mechanism, the clinical implication is clear: patients who show only partial benefit at three or six months should not abandon VNS, because the full effect may take one to three years to develop.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Current Devices: Open-Loop and Closed-Loop VNS
VNS was first FDA-approved for drug-resistant epilepsy in 1997, making it the neuromodulation therapy with the longest track record in neurology. The technology has evolved through several device generations, with the most significant advance being the introduction of closed-loop stimulation.
Open-loop (traditional) VNS delivers stimulation at fixed intervals — typically 30 seconds on, 5 minutes off — regardless of what the brain is doing. Patients also carry a magnet that can trigger extra stimulation when they sense a seizure beginning (or when a caregiver recognises one). The duty cycle, pulse width, frequency, and output current are programmed by the neurologist and adjusted over follow-up visits. This approach has accumulated decades of safety and efficacy data, with the progressive improvement pattern described above.
Closed-loop VNS — available in LivaNova’s AspireSR (Model 106) and SenTiva (Model 1000) devices — adds an automatic stimulation mode called AutoStim. The device continuously monitors heart rate through the vagus nerve electrode. When it detects a sudden heart rate increase consistent with a seizure (ictal tachycardia), it delivers an extra burst of stimulation automatically, without the patient or caregiver needing to intervene. This matters because approximately 80 percent of epileptic seizures are accompanied by ictal tachycardia, and many seizures — particularly those occurring during sleep — are not detected by patients or caregivers in time for manual magnet activation.
An American Epilepsy Society 2025 study of 75 patients with drug-resistant epilepsy (mean follow-up 51.3 months with AutoStim) reported that 69.3 percent achieved greater than 50 percent seizure reduction, and 25.3 percent achieved greater than 90 percent reduction. In the same group’s earlier series using traditional VNS without AutoStim, only 10.6 percent had reached the 90 percent reduction threshold — suggesting that closed-loop detection and response substantially improves outcomes for the most treatment-resistant patients. The current generation SenTiva also features scheduled duty cycle changes (day versus night programming), a smaller form factor, and MRI-conditional labelling under specific protocols.
Who Is a Candidate for VNS
VNS is approved as adjunctive therapy for drug-resistant epilepsy — meaning epilepsy that has not been adequately controlled by at least two appropriately chosen and tolerated anti-seizure medications. It is not a first-line treatment and does not replace medication; rather, it is added to the existing regimen when medications alone are insufficient.
The strongest candidates are patients with drug-resistant focal epilepsy who are not candidates for resective surgery (either because the seizure focus cannot be localised, because it is in eloquent cortex, or because prior surgery has failed). However, VNS is also used in generalised epilepsy syndromes, including Lennox-Gastaut syndrome and Dravet syndrome, where its broad mechanism of action — working through brainstem networks rather than targeting a specific cortical focus — provides benefit across seizure types.
Before implantation, patients should understand the timeline. VNS is not a rapid-onset therapy. The device is gradually titrated over weeks to months, and the full anti-seizure effect may take one to three years to develop. Side effects during stimulation are generally mild: voice hoarseness or alteration (due to the recurrent laryngeal nerve running adjacent to the vagus), coughing, throat tingling, and occasional shortness of breath. These typically diminish as the patient acclimates and as stimulation parameters are optimised. Serious complications — infection at the implant site, lead fracture, vocal cord paralysis — are rare, occurring in fewer than 2 percent of cases.
Non-Invasive Alternatives: taVNS for Epilepsy
Transcutaneous auricular VNS (taVNS) — stimulation of the vagus nerve’s auricular branch at the ear through surface electrodes — is being investigated as a non-surgical alternative for epilepsy. The auricular branch (Arnold’s nerve) is the only point where vagal afferent fibres reach the body surface, and electrical stimulation at the tragus or cymba conchae activates some of the same brainstem pathways as implanted VNS.
The evidence for taVNS in epilepsy remains early-stage. A 2025 Frontiers in Neurology randomised controlled trial tested taVNS in 40 patients with epilepsy comorbid with migraine over 24 weeks. Both the active taVNS group and the sham group showed seizure reduction, limiting conclusions about specific efficacy. Improvements in anxiety, depression, and quality-of-life scores were more clearly separated from sham. An earlier epilepsy-only trial reported 8 of 47 patients achieving seizure freedom and 19 of 47 with reduced seizure frequency, though these numbers come from a study without rigorous sham control.
The practical limitation of taVNS for epilepsy is that the stimulation intensity reaching brainstem nuclei through skin-surface electrodes is substantially lower than with an implanted device delivering current directly to the cervical vagus trunk. For patients with truly drug-resistant epilepsy — the population for whom VNS is indicated — taVNS has not yet demonstrated efficacy comparable to implanted VNS. It may be most relevant as a screening tool: some clinicians use a trial of taVNS to assess whether a patient responds to vagal afferent stimulation before proceeding with surgical implantation.
Beyond Seizure Reduction: Cognitive and Mood Effects
VNS’s activation of the locus coeruleus and dorsal raphe nucleus — the brain’s primary norepinephrine and serotonin sources — means its effects extend beyond seizure control. Norepinephrine is essential for attention and cognitive flexibility, and serotonin regulates mood and emotional processing. Chronic VNS modulates both systems continuously.
Clinical registries have documented improvements in alertness, verbal fluency, and quality of life in VNS-treated patients, sometimes independent of seizure reduction. The VNS device also carries a separate FDA approval for treatment-resistant depression (granted in 2005), reflecting the overlap between its anti-seizure and mood-regulating mechanisms. For patients with epilepsy who experience comorbid depression — a common combination, affecting approximately 30 percent of people with drug-resistant epilepsy — VNS offers the unusual advantage of addressing both conditions through a single intervention.
The most important cognitive benefit may be indirect. Chronic uncontrolled seizures cause progressive hippocampal damage and cognitive decline. By reducing seizure frequency and promoting hippocampal neurogenesis, VNS may slow or partially reverse this process — though separating the neuroprotective effects of VNS from the benefits of seizure reduction itself remains a research challenge.
VNS works because the vagus nerve provides a direct anatomical pathway from a neck electrode to the brainstem nuclei that regulate cortical excitability — but understanding why it takes months to reach full effect, and how closed-loop detection improves outcomes, requires knowing the nerve’s anatomy in detail. My Vagus Nerve & Me maps the full vagal pathway from brainstem to abdomen, explains the mechanisms behind electrical stimulation, and covers what the latest clinical evidence shows for every major VNS application. Get My Vagus Nerve & Me eBook and understand the science behind the therapy.
